Doubling Down: Will Large Increases in the NIH Budget Promote More Meaningful Medical Innovation?

Abstract

AbstractKesselheim proposes doubling the NIH’s budget to promote clinically meaningful pharmaceutical innovation. Since the effects of a previous doubling (from 1998-2003) were mixed, I argue that policymakers should couple future budget growth with investments in experimentation and evaluation.